552 related articles for article (PubMed ID: 26397337)
1. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
Zhu QL; Faquin WC; Samir AE
AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
[TBL] [Abstract][Full Text] [Related]
2. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
[TBL] [Abstract][Full Text] [Related]
3. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
[TBL] [Abstract][Full Text] [Related]
5. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules.
McIver B; Castro MR; Morris JC; Bernet V; Smallridge R; Henry M; Kosok L; Reddi H
J Clin Endocrinol Metab; 2014 Nov; 99(11):4069-77. PubMed ID: 24780044
[TBL] [Abstract][Full Text] [Related]
6. Multicenter clinical experience with the Afirma gene expression classifier.
Alexander EK; Schorr M; Klopper J; Kim C; Sipos J; Nabhan F; Parker C; Steward DL; Mandel SJ; Haugen BR
J Clin Endocrinol Metab; 2014 Jan; 99(1):119-25. PubMed ID: 24152684
[TBL] [Abstract][Full Text] [Related]
7. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
Hang JF; Westra WH; Cooper DS; Ali SZ
Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification of cytologically indeterminate thyroid nodules with nondiagnostic or benign cytology on repeat FNA: Implications for molecular testing and surveillance.
Hall EA; Hartzband P; VanderLaan PA; Nishino M
Cancer Cytopathol; 2023 May; 131(5):313-324. PubMed ID: 36792948
[TBL] [Abstract][Full Text] [Related]
9. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
[No Abstract] [Full Text] [Related]
10. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?
Yang SE; Sullivan PS; Zhang J; Govind R; Levin MR; Rao JY; Moatamed NA
Cancer Cytopathol; 2016 Feb; 124(2):100-9. PubMed ID: 26422098
[TBL] [Abstract][Full Text] [Related]
11. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
[TBL] [Abstract][Full Text] [Related]
12. Use of the Afirma Xpression Atlas for cytologically indeterminate, Afirma Genomic Sequencing Classifier suspicious thyroid nodules: Clinicopathologic analysis with postoperative molecular testing.
Munoz-Zuluaga CA; Heymann JJ; Solomon JP; Patel A; Siddiqui MT; Scognamiglio T; Gokozan HN
Am J Clin Pathol; 2024 May; 161(5):463-468. PubMed ID: 38104250
[TBL] [Abstract][Full Text] [Related]
13. UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.
Villabona CV; Mohan V; Arce KM; Diacovo J; Aggarwal A; Betancourt J; Amer H; Jose T; DeSantis P; Cabral J
Endocr Pract; 2016 Oct; 22(10):1199-1203. PubMed ID: 27409819
[TBL] [Abstract][Full Text] [Related]
14. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology.
Na DG; Kim JH; Sung JY; Baek JH; Jung KC; Lee H; Yoo H
Thyroid; 2012 May; 22(5):468-75. PubMed ID: 22304417
[TBL] [Abstract][Full Text] [Related]
15. Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome.
Chaudhary S; Hou Y; Shen R; Hooda S; Li Z
Acta Cytol; 2016; 60(3):205-10. PubMed ID: 27344463
[TBL] [Abstract][Full Text] [Related]
16. Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs from Other Indeterminate Thyroid Nodules.
Brauner E; Holmes BJ; Krane JF; Nishino M; Zurakowski D; Hennessey JV; Faquin WC; Parangi S
Thyroid; 2015 Jul; 25(7):789-96. PubMed ID: 25962906
[TBL] [Abstract][Full Text] [Related]
17. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
[TBL] [Abstract][Full Text] [Related]
18. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
19. The first Canadian experience with the Afirma® gene expression classifier test.
Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
[TBL] [Abstract][Full Text] [Related]
20. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
